Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rogaratinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 known ✓ | P11362 | 20/20 | 1.00 |
| ▸ | FGFR3 known ✓ | P22607 | 13/20 | 1.00 |
| ▸ | FGFR4 known ✓ | P22455 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rogaratinib SCHEMBL15023004 | 1.00 | FGFR1 (1.00) | FGFR1FGFR3FGFR4 | |
| Rogaratinib SCHEMBL22288911 | 0.99 | FGFR1 (0.99) | FGFR1FGFR3FGFR4 | |
| Rogaratinib SCHEMBL15023316 | 0.99 | FGFR1 (0.99) | FGFR1FGFR3FGFR4 | |
| Rogaratinib SCHEMBL29542499 | 0.99 | FGFR1 (0.97) | FGFR1FGFR3FGFR4 | |
| SCHEMBL15023375 | 0.94 | FGFR1 (1.00) | FGFR1FGFR3FGFR4 | |
| SCHEMBL15023167 | 0.94 | FGFR1 (1.00) | FGFR1FGFR3FGFR4 | |
| SCHEMBL22315228 | 0.94 | FGFR1 (0.89) | FGFR1FGFR3FGFR4 | |
| Hydrochloric Acid SCHEMBL15023352 | 0.94 | FGFR1 (0.99) | FGFR1FGFR3FGFR4 | |
| SCHEMBL15023243 | 0.94 | FGFR1 (1.00) | FGFR1FGFR3FGFR4 | |
| SCHEMBL20643278 | 0.93 | FGFR1 (0.88) | FGFR1FGFR3FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 393 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4701664-A1 | METHODS OF TREATING TKI-RESISTANT AND SDH-DEFICIENT GIST | Guangzhou Healthquest Pharma Co., Ltd. (CN) | 2026-03-04 | — | — | EP | claimed |
| EP-4683635-A1 | USES OF A CHECKPOINT KINASE 1 (CHK1) INHIBITOR | Boundless Bio, Inc. (US) | 2026-01-28 | — | — | EP | claimed |
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | ZOUNEK ALEX (DE) | 2025-12-18 | — | — | US | claimed |
| EP-4619027-A2 | ANTI-FGFR3 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS AND METHODS OF USE THEREOF | Regeneron Pharmaceuticals, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| US-20250235456-A1 | METHODS OF USE FOR AZA-QUINAZOLINE COMPOUNDS | IAMBIC THERAPEUTICS, INC. | 2025-07-24 | — | — | US | claimed |
| US-12357632-B2 | Methods of treating cholangiocarcinoma | QED THERAPEUTICS, INC. (US) | 2025-07-15 | — | — | US | claimed |
| EP-4551565-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | Zounek, Alex (DE) | 2025-05-14 | — | — | EP | claimed |
| US-20240408047-A1 | HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS FOR THE TREATMENT OF BLADDER CANCER | NIKANG THERAPEUTICS, INC. | 2024-12-12 | — | — | US | claimed |
| WO-2024222902-A1 | METHODS OF TREATING TKI-RESISTANT AND SDH-DEFICIENT GIST | GUANGZHOU HEALTHQUEST PHARMA CO., LTD. (CN) | 2024-10-31 | — | — | WO | claimed |
| US-20240327928-A1 | METHOD FOR IDENTIFYING RESPONSIVENESS TO FIBROBLAST GROWTH FACTOR RECEPTOR 1 INHIBITOR THERAPY | UNIV KOELN (DE) | 2024-10-03 | — | — | US | claimed |
| WO-2023069372-A1 | HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS FOR THE TREATMENT OF BLADDER CANCER | NIKANG THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | claimed |
| WO-2023017133-A1 | METHOD FOR IDENTIFYING RESPONSIVENESS TO FIBROBLAST GROWTH FACTOR RECEPTOR 1 INHIBITOR THERAPY | UNIVERSITÄT ZU KÖLN (DE) | 2023-02-16 | — | — | WO | claimed |
| EP-4134451-A1 | METHOD FOR IDENTIFYING RESPONSIVENESS TO FIBROBLAST GROWTH FACTOR RECEPTOR 1 INHIBITOR THERAPY | Universität zu Köln (DE) | 2023-02-15 | — | — | EP | claimed |
| US-20220356194-A1 | PROCESS FOR PREPARING BENZOTHIOPHEN-2YL BORONATE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-11-10 | — | — | US | claimed |
| WO-2022174234-A2 | BIOMARKERS FOR CANCER TREATMENT | FOUNDATION MEDICINE, INC. (US) | 2022-08-18 | — | — | WO | claimed |
| US-20220233536-A1 | METHODS OF TREATING CHOLANGIOCARCINOMA | QED THERAPEUTICS, INC. | 2022-07-28 | — | — | US | claimed |
| WO-2022125967-A2 | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | ERASCA, INC. (US) | 2022-06-16 | — | — | WO | claimed |
| WO-2022073994-A1 | LMP7-SELECTIVE INHIBITORS FOR THE TREATMENT OF BLOOD DISORDERS AND SOLID TUMORS | MERCK PATENT GMBH (DE) | 2022-04-14 | — | — | WO | claimed |
| EP-3976042-A2 | METHODS OF TREATING CHOLANGIOCARCINOMA | QED Therapeutics, Inc. (US) | 2022-04-06 | — | — | EP | claimed |
| WO-2020243273-A9 | METHODS OF TREATING CHOLANGIOCARCINOMA | QED THERAPEUTICS, INC. (US) | 2022-02-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | KIT, CTSL, PAICS | FGFR1 42/4885FGFR3 63/4885FGFR4 282/4885 |
| US-20220356194-A1 | PROCESS FOR PREPARING BENZOTHIOPHEN-2YL BORONATE | BPGM, BRCA1, BRAP | FGFR1 836/4885FGFR3 1202/4885FGFR4 431/4885 |
| US-12357632-B2 | Methods of treating cholangiocarcinoma | KRAS, SLC10A2, SLC10A1 | FGFR1 18/4885FGFR3 12/4885FGFR4 25/4885 |
| US-20240408047-A1 | HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS FOR THE TREATMENT OF BLADDER CANCER | HIF1AN, HIF1A, EGLN2 | FGFR1 2056/4885FGFR3 378/4885FGFR4 1293/4885 |
| US-20250235456-A1 | METHODS OF USE FOR AZA-QUINAZOLINE COMPOUNDS | AZI2, TPMT, HDAC10 | FGFR1 3506/4885FGFR3 4067/4885FGFR4 4248/4885 |
| US-20220233536-A1 | METHODS OF TREATING CHOLANGIOCARCINOMA | KRAS, SLC10A2, SLC10A1 | FGFR1 18/4885FGFR3 12/4885FGFR4 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.